IL150992A0 - Caspase activated prodrugs therapy - Google Patents
Caspase activated prodrugs therapyInfo
- Publication number
- IL150992A0 IL150992A0 IL15099201A IL15099201A IL150992A0 IL 150992 A0 IL150992 A0 IL 150992A0 IL 15099201 A IL15099201 A IL 15099201A IL 15099201 A IL15099201 A IL 15099201A IL 150992 A0 IL150992 A0 IL 150992A0
- Authority
- IL
- Israel
- Prior art keywords
- activated prodrugs
- caspase activated
- prodrugs therapy
- therapy
- caspase
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title 1
- 108010076667 Caspases Proteins 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18477900P | 2000-02-24 | 2000-02-24 | |
| PCT/US2001/005709 WO2001062300A2 (en) | 2000-02-24 | 2001-02-22 | Caspase activated prodrugs therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL150992A0 true IL150992A0 (en) | 2003-02-12 |
Family
ID=22678303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15099201A IL150992A0 (en) | 2000-02-24 | 2001-02-22 | Caspase activated prodrugs therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070104719A1 (pl) |
| EP (1) | EP1257296A2 (pl) |
| JP (1) | JP2003523407A (pl) |
| KR (1) | KR20020082227A (pl) |
| CN (1) | CN1406137A (pl) |
| AU (1) | AU783679B2 (pl) |
| BR (1) | BR0108930A (pl) |
| CA (1) | CA2399255A1 (pl) |
| HU (1) | HUP0300024A2 (pl) |
| IL (1) | IL150992A0 (pl) |
| MX (1) | MXPA02007939A (pl) |
| NZ (1) | NZ520458A (pl) |
| PL (1) | PL358187A1 (pl) |
| WO (1) | WO2001062300A2 (pl) |
| ZA (1) | ZA200206105B (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| AU2002239403A1 (en) | 2000-12-01 | 2002-06-11 | The Johns Hopkins University | Tissue specific prodrugs |
| WO2003066003A2 (en) | 2002-02-07 | 2003-08-14 | Massachusetts Institute Of Technology | Anti-pathogen treatements |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| AU2004248138B2 (en) | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| CA2679643A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Procaspase 8-mediated disease targeting |
| CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CN102105156B (zh) | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
| WO2009141827A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions |
| WO2009141823A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 |
| RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
| WO2011037916A1 (en) * | 2009-09-28 | 2011-03-31 | Quest Diagnostics Investments Incorporated | Method leukemia diagnosis using caspase-3 |
| TW201119676A (en) | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2601218A4 (en) | 2010-08-03 | 2015-02-18 | Abbvie Inc | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
| BR112013004581A2 (pt) | 2010-08-26 | 2017-06-27 | Abbvie Inc | imunoglobulinas de domínio variável dual e seus usos |
| KR20130136494A (ko) * | 2010-12-29 | 2013-12-12 | 애로우헤드 리서치 코오포레이션 | 효소 민감성 결합을 갖는 Ｉｎ Ｖｉｖｏ 폴리뉴클레오티드 전달 컨쥬게이트 |
| US9408910B2 (en) | 2011-03-02 | 2016-08-09 | Korea Institute Of Science And Technology | Anticancer prodrug activated by radiation or ultraviolet treatment and use thereof |
| JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン |
| IN2014MN01819A (pl) | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| RU2636043C2 (ru) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| CA2951049C (en) * | 2014-06-03 | 2023-01-03 | Jiarui Biopharmaceuticals, Ltd. | Peptide-drug conjugates |
| US10125105B2 (en) | 2014-06-11 | 2018-11-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
| US9593080B1 (en) | 2014-06-11 | 2017-03-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
| US10047061B2 (en) | 2014-06-11 | 2018-08-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Water-soluble triazabutadienes |
| WO2016080626A2 (en) | 2014-11-20 | 2016-05-26 | Pharosgen | Prodrugs activated by caspase |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US10954195B2 (en) | 2015-08-11 | 2021-03-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted triazenes protected from degradation by carboxylation of N1 |
| JP2019526526A (ja) * | 2016-05-04 | 2019-09-19 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物 |
| WO2018023130A1 (en) | 2016-07-29 | 2018-02-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Triazabutadienes as cleavable cross-linkers |
| WO2019091384A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| CA3155093A1 (en) * | 2019-09-19 | 2021-03-25 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675187A (en) * | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| WO1999006072A1 (en) * | 1997-07-30 | 1999-02-11 | Boehringer Mannheim Corporation | Cyclized prodrugs |
| JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
| US6379950B1 (en) * | 1998-01-09 | 2002-04-30 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
| US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
| WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
-
2001
- 2001-02-22 AU AU41667/01A patent/AU783679B2/en not_active Ceased
- 2001-02-22 HU HU0300024A patent/HUP0300024A2/hu unknown
- 2001-02-22 MX MXPA02007939A patent/MXPA02007939A/es not_active Application Discontinuation
- 2001-02-22 NZ NZ520458A patent/NZ520458A/en not_active IP Right Cessation
- 2001-02-22 WO PCT/US2001/005709 patent/WO2001062300A2/en not_active Ceased
- 2001-02-22 CA CA002399255A patent/CA2399255A1/en not_active Abandoned
- 2001-02-22 BR BR0108930-7A patent/BR0108930A/pt not_active IP Right Cessation
- 2001-02-22 IL IL15099201A patent/IL150992A0/xx unknown
- 2001-02-22 CN CN01805618A patent/CN1406137A/zh active Pending
- 2001-02-22 KR KR1020027011059A patent/KR20020082227A/ko not_active Ceased
- 2001-02-22 PL PL01358187A patent/PL358187A1/pl not_active Application Discontinuation
- 2001-02-22 JP JP2001561363A patent/JP2003523407A/ja active Pending
- 2001-02-22 EP EP01912935A patent/EP1257296A2/en not_active Withdrawn
-
2002
- 2002-07-31 ZA ZA200206105A patent/ZA200206105B/xx unknown
-
2006
- 2006-09-29 US US11/537,578 patent/US20070104719A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1257296A2 (en) | 2002-11-20 |
| CA2399255A1 (en) | 2001-08-30 |
| BR0108930A (pt) | 2002-12-10 |
| ZA200206105B (en) | 2003-07-31 |
| JP2003523407A (ja) | 2003-08-05 |
| AU783679B2 (en) | 2005-11-24 |
| KR20020082227A (ko) | 2002-10-30 |
| NZ520458A (en) | 2005-02-25 |
| WO2001062300A2 (en) | 2001-08-30 |
| PL358187A1 (pl) | 2004-08-09 |
| WO2001062300A3 (en) | 2002-04-25 |
| US20070104719A1 (en) | 2007-05-10 |
| HUP0300024A2 (en) | 2003-05-28 |
| AU4166701A (en) | 2001-09-03 |
| CN1406137A (zh) | 2003-03-26 |
| MXPA02007939A (es) | 2003-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150992A0 (en) | Caspase activated prodrugs therapy | |
| GB0009606D0 (en) | Therapeutic combinations | |
| GB0028429D0 (en) | Therapy | |
| GB0012671D0 (en) | Therapeutic agents | |
| GB0003397D0 (en) | Therapeutic agents | |
| GB0004003D0 (en) | Therapeutic agents | |
| GB0018473D0 (en) | Therapeutic agents | |
| GB0027561D0 (en) | Therapeutic agents | |
| GB0005789D0 (en) | Therapeutic agents | |
| GB0012214D0 (en) | Therapeutic agents | |
| GB0008696D0 (en) | Therapeutic agents | |
| GB0023610D0 (en) | Therapeutic agents | |
| GB0000564D0 (en) | Therapeutic agents | |
| AU144325S (en) | Therapy device | |
| GB0001710D0 (en) | Therapeutic treatment | |
| GB0020721D0 (en) | Therapeutic agents | |
| GB0017518D0 (en) | Therapeutic agents | |
| PL342829A1 (en) | Bioenergetical therapeutic device | |
| GB0007376D0 (en) | Therapeutic agents | |
| AU2096002A (en) | Therapeutic treatment | |
| GB0030067D0 (en) | Therapeutic agent | |
| GB2364602B (en) | Therapeutic device | |
| GB0022988D0 (en) | Therapeutic agents | |
| GB0014908D0 (en) | Combination therapy | |
| GB0007740D0 (en) | Combination therapy |